SB 030

Drug Profile

SB 030

Alternative Names: SB-030; SBCV 030

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SYMIC Biomedical
  • Developer Symic Bio
  • Class Proteoglycans; Vascular disorder therapies
  • Mechanism of Action Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Peripheral arterial disorders

Most Recent Events

  • 01 Nov 2017 Interim efficacy data from the phase I/II SHIELD trial in Peripheral arterial disorders released by Symic Bio
  • 26 Aug 2017 Preclinical pharmacodynamics data in Peripheral arterial disorders presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology (ESC-CARD-2017)
  • 22 May 2017 Symic Bio plans the phase III trial for Peripheral arterial disorders (Prevention) in USA in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top